🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to researchers.

A Global Public Health Issue

Cases of gonorrhoea are escalating worldwide, with figures suggesting in excess of 82 million new cases per year. Especially elevated rates are observed in the African continent and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely step in the context of growing infection rates, the spread of superbugs and the extremely scarce therapeutic options at this time.”

Medical experts are increasingly worried about the increase in treatment-resistant strains. The global health body has designated it as a "critical concern". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Secure Approval

One new antibiotic, also known as Nuzolvence, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers believe that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GSK, gained clearance in close succession. This treatment, which is additionally indicated for UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This milestone marks a significant shift in the management of highly resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Testing Data and Worldwide Availability

As per findings released by a major medical journal, the new drug cured over nine in ten of cases of the STI. This puts it on an equal footing with the typical regimen, which involves two antibiotics. The study included over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the rights to register and commercialise the drug in many low-income and middle-income countries.

Clinicians directly involved have voiced optimism. Access to a one-pill regimen of this kind is described as a "revolutionary step" for public health efforts. This is viewed as essential to lessen the impact of the disease for people and to halt the transmission of extremely resistant gonorrhoea worldwide.